Pure Global
NCT06241638

Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers

Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers, Combined With Dapagliflozin as Type Two Diabetes Mellitus Routine Treatment
Al-Balqa Applied University·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Mellitus
Drug/Device/Intervention
Vitamin B12 0.5 MG/ACTUAT
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Al-Balqa Applied University
Location
Salt, Jordan
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2022
End date
Jun 30, 2023
Enrollment
80 participants
Primary outcome

HbA1c in the two groups

Summary

The current study was conducted to evaluate the prognostic implications of vitamin B12
 admission on BMI and HbA1c levels in type 2 diabetic patients treated with Dapagliflozin as a
 routine medication.

ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsUnspecified diabetes mellitus with unspecified complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06241638
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06241638 through Pure Global AI's free database. This phase not specified trial is sponsored by Al-Balqa Applied University and is currently Completed. The study focuses on Diabetes Mellitus. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.